PRESS RELEASE

STOCKHOLM, OCTOBER 30, 2023

Invitation to presentation of RaySearch's interim report for the third quarter of 2023

Analysts, investors, and the media are invited to a presentation of RaySearch's interim report for the third quarter of 2023 on November 17, 2023, at 10.00 am CET. The report will be published on November 17, 2023, at 07.45 am and will be available together with presentation slides on raysearchlabs.com. Johan Löf, founder and CEO, and Annika Blondeau Henriksson, interim CFO, will present the company's development in a webcast. After the presentation (held in English) there is the opportunity to ask questions.

Link to webcast: RaySearch Q3, 2023.

Or dial in to join the webcast:

Sweden: +46 (0) 8 5051 0031

United Kingdom: +44 (0) 207 107 06 13 United States: +1 (1) 631 570 56 13

About RaySearch

RaySearch Laboratories AB (publ) is a medical technology company that develops innovative software solutions for improved cancer treatment. RaySearch markets the RayStation®* treatment planning system (TPS) and the oncology information system (OIS) RayCare®*. The most recent additions to the RaySearch product line are RayIntelligence® and RayCommand®*. RayIntelligence is an oncology analytics system (OAS) which enables cancer clinics to collect, structure and analyze data. RayCommand, a treatment control system (TCS), is designed to link the treatment machine and the treatment planning and oncology information systems.

RaySearch's software has been sold to over 900 clinics in more than 40 countries. The company was founded in 2000 as a spin-off from the Karolinska Institute in Stockholm and the share has been listed on Nasdaq Stockholm since 2003. More information is available at raysearchlabs.com.

For more information, please contact:

Johan Löf, founder and CEO, RaySearch Laboratories AB (publ) Telephone: +46 (0) 8 510 530 00 johan.lof@raysearchlabs.com

Annika Blondeau Henriksson, interim CFO, RaySearch Laboratories AB (publ)

Telephone: +46 (0) 8 510 530 00 annika.henriksson@raysearchlabs.com

^{*} Subject to regulatory clearance in some markets.